EUVIMEDAtrasti EUVIMED
KohortenstudieStudienprotokollOpen access

Molecular and Pharmacogenetic marker evaluation in relation to the toxicity and clinical response of acute lymphoblastic leukemia treatment in Indian children (MPGx-INDALL) – A Prospective observational cohort study protocol (Preprint)

Swetambri Sharma iD, Shuvadeep Ganguly iD, Kamali Murugadoss iD, Smita Kayal iD, Swaminathan Keerthivasagam iD, Jaikumar Ramamoorthy, Archna Singh iD, Deepam Pushpam iD, Jayanthi Mathaiyan iD, Yvonne Gloor iD, Frederic Baleydier iD, Marc Ansari iD and 3 more

JMIR Research Protocols · 2025

DOI: 10.2196/79865 ↗

At a glance

Kohortenstudie in JMIR Research Protocols, 2025. Written by Swetambri Sharma and 14 co-authors. Institution: Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India. Major MEDLINE topics: Precursor Cell Lymphoblastic Leukemia-Lymphoma. 31 references. The full text is freely available in PubMed Central. Funded by: Swiss National Science Foundation.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

Understanding interindividual variability in treatment response and toxicity is essential for optimizing outcomes in pediatric acute lymphoblastic leukemia (ALL). Molecular and pharmacogenetic markers hold promise in predicting treatment efficacy and adverse effects, particularly in genetically diverse populations. This protocol outlines the methodology for a prospective, nonrandomized observational cohort designed to evaluate molecular and pharmacogenetic factors associated with treatment response and toxicity in Indian children diagnosed with ALL.

Objective

The primary objective is to identify genetic markers associated with treatment-related toxicity and therapeutic response. Secondary objectives include evaluating associations between the occurrence of early toxicities and quality of life during active ALL treatment, specific pharmacogenetic variants, and survival outcomes along with generating data to support the future implementation of personalized treatment strategies in Indian children with ALL.

Methods

In this prospective, observational cohort, 556 children (≤18 years of age) with newly diagnosed ALL treated under the Indian Childhood Collaborative Leukemia-Acute Lymphoblastic Leukemia 2014 (ICiCLe-ALL-14) protocol at two Indian centers will be enrolled, aiming for a minimum of 500 evaluable children. Eligible participants will be enrolled prior to the initiation of chemotherapy and followed longitudinally throughout treatment. Clinical and laboratory data (demographics, nutritional assessment, quality of life, comorbidities, treatment regimen, toxicity graded by Common Terminology Criteria for Adverse Events v5.0, remission status, and survival) will be collected at predefined intervals up to day 100 of the maintenance phase. Germline and somatic DNA will be sampled at diagnosis and remission. The first phase will use whole-exome sequencing to discover candidate variants by implementing a candidate gene prioritization strategy. The second phase will genotype the top candidates in the full cohort using array technology. Associations with early treatment-related toxicities, steroid response, and survival will be tested by multivariable regression and Cox models. A machine learning approach with pharmacogenetic predictors as classifiers will be implemented further with cross-validation and sensitivity analyses.

Results

Ethical committees approved the protocol version 1.0 in 2020: IEC-1167/06.11.2020 (All India Institute of Medical Sciences, New Delhi), JIP/IEC/2020/201 (Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry), and AO_2021-00048 (UNIGE, Geneva). Funding was received from Swiss National Science Foundation, Switzerland; Department of Biotechnology, India; and CANSEARCH Foundation, Switzerland. Recruitment began in December 2022 and is likely to conclude by 2027. A comprehensive analysis of the complete study cohort is anticipated to be completed by 2027.

Conclusions

The MPGx-INDALL (Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children) study will generate actionable insights for individualized ALL therapy in India via systematically evaluating germline and somatic markers in a large ethnically distinct cohort.

Subjects

MeSH terms (MEDLINE)

Precursor Cell Lymphoblastic Leukemia-LymphomaAdolescentChildChild, PreschoolFemaleHumansInfantMaleCohort StudiesIndiaObservational Studies as TopicPharmacogeneticsProspective StudiesQuality of LifeTreatment Outcome

Author keywords

ICiCLeacute lymphoblastic leukemiagermline variantspediatric ALLpharmacogeneticsquality of lifesequencingsomatic variantstoxicitytreatment-related toxicity

Authors and institutions

  • Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research, Dhanvantri Nagar, Puducherry, 605006, India, 91 7675935408.
  • Department of Pediatrics, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India.
  • Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
  • Department of Pharmacology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India.
  • Department of Pediatrics, Gynecology and Obstetrics, CANSEARCH Research Platform in Pediatric Oncology and Haematology, University of Geneva, Geneva, Switzerland.

ORCID profiles: Swetambri Sharma, Shuvadeep Ganguly, Kamali Murugadoss, Smita Kayal, Swaminathan Keerthivasagam, Archna Singh, Deepam Pushpam, Jayanthi Mathaiyan, Yvonne Gloor, Frederic Baleydier, Marc Ansari, Sameer Bakhshi, Biswajit Dubashi, Chakradhara Rao S Uppugunduri

Funding

  • Swiss National Science Foundation

Cite

APA

Sharma, S., Ganguly, S., Murugadoss, K., Kayal, S., Keerthivasagam, S., Ramamoorthy, J., Singh, A., Pushpam, D., Mathaiyan, J., Gloor, Y., Baleydier, F., Ansari, M., Bakhshi, S., Dubashi, B., & Uppugunduri, C. R. S. (2025). Molecular and Pharmacogenetic marker evaluation in relation to the toxicity and clinical response of acute lymphoblastic leukemia treatment in Indian children (MPGx-INDALL) – A Prospective observational cohort study protocol (Preprint). JMIR Research Protocols. https://doi.org/10.2196/79865

Vancouver

Sharma S, Ganguly S, Murugadoss K, Kayal S, Keerthivasagam S, Ramamoorthy J, et al. Molecular and Pharmacogenetic marker evaluation in relation to the toxicity and clinical response of acute lymphoblastic leukemia treatment in Indian children (MPGx-INDALL) – A Prospective observational cohort study protocol (Preprint). JMIR Research Protocols. 2025. doi:10.2196/79865

BibTeX
@article{Sharma2025,
  author = {Sharma, Swetambri and Ganguly, Shuvadeep and Murugadoss, Kamali and Kayal, Smita and Keerthivasagam, Swaminathan and Ramamoorthy, Jaikumar and Singh, Archna and Pushpam, Deepam and Mathaiyan, Jayanthi and Gloor, Yvonne and Baleydier, Frederic and Ansari, Marc and Bakhshi, Sameer and Dubashi, Biswajit and Uppugunduri, Chakradhara Rao S},
  title = {Molecular and Pharmacogenetic marker evaluation in relation to the toxicity and clinical response of acute lymphoblastic leukemia treatment in Indian children (MPGx-INDALL) – A Prospective observational cohort study protocol (Preprint)},
  journal = {JMIR Research Protocols},
  year = {2025},
  doi = {10.2196/79865}
}
Start for free →